Ad

CU6 – Clarity Pharmaceuticals Ltd

🔒

Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month

Ad

Recommendation Rating

1.67

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 1.11

Low: 0.82

High: 1.6

Total Analysts: 3

Company Profile

Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing products to address the growing need for the use of radiopharmaceuticals in oncology. It is developing targeted copper theranostics-based on its SAR Technology Platform for the treatment of cancer in children and adults. Its lead radiopharmaceutical products include SARTATE, SAR-Bombesin and SAR-bisPSMA. SARTATE targets somatostatin receptor 2 (SSTR2) expressing cancers, including neuroblastoma and neuroendocrine tumors. SAR-Bombesin targets gastrin-releasing peptide receptor (GRPr) expressing cancers, including prostate cancer and breast cancer. SAR-bisPSMA targets prostate-specific membrane antigen (PSMA) expressing cancers, including prostate cancer. Its SAR Technology platform employs a superior chelator (cage) for copper used in the diagnosis and treatment of a range of cancers. The technology can be employed for targeted cancer therapy.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Ad

Responses